Merge Reports Subscription Backlog Up 82%
CHICAGO, Feb. 18, 2013 (GLOBE NEWSWIRE) -- Merge Healthcare Incorporated (NASDAQ: MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, today announced its financial and business results for the fourth quarter of 2012. Merge also confirmed the conclusion of its previously announced evaluation of strategic alternatives.
"After careful evaluation, we have determined that the alternatives evaluated did not offer more value than our own strategic plan," said Jeff Surges, CEO of Merge Healthcare. "We will continue to build upon the proven success over the last few years and further leverage our portfolio of solutions into a more present and ready marketplace than ever before. In addition, we are reiterating annual guidance for 2013 on revenue, adjusted EBITDA and subscription backlog growth."
Financial Highlights:
- Sales increased to $64.7 million ($65.1 million on a pro forma basis) in the quarter, from $64.1 million ($65.1 million on a pro forma basis) in the fourth quarter of 2011;
- Adjusted EBITDA, before consideration of one-time non-cash charges, was $13.9 million, representing 21% of pro forma revenue in the quarter, compared to $15.1 million and 23% in the fourth quarter of 2011 (see table at end of this press release for reconciliation);
- Subscription-based pricing arrangements generated 13.5% of total sales in the quarter and subscription backlog grew 13% in the quarter and 82% for the year; and
- Reiterating 2013 guidance of revenue in the range of $265 - $275 million with an adjusted EBITDA range of 22-24% and expected subscription backlog growth by the end of 2013 of at least $25 million.
- Added 12 iConnect® contracts with leading healthcare systems including Northeast Georgia, Health Ventures, St. John Providence Health System, Edward Hospital and Altru Health System;
- Executed 17 contracts for Merge Cardiology solutions with clients including Borgess Medical Center, DuPage Medical Center, Boca Raton Regional Hospital, St. Thomas and Palos Hospital among others;
- Bookings growth in sales to end-user customers in the Healthcare segment grew by 38% in 2012;
- Merge clients will be eligible to receive an estimated total of $14 million in Meaningful Use incentive payments by utilizing Merge's Meaningful Use solutions for Radiology and Orthopedics; and
- eClinical signed over 190 contracts in the quarter driving year-over-year bookings growth of 79%.
| Q4 2012 | Q4 2011 | |
| Net sales | $64.7 | $64.1 |
| Operating income | (8.4) | 8.3 |
| Net loss attributable to common shareholders | (17.3) | (1.3) |
| Net income (loss) per diluted share | ($0.19) | ($0.01) |
| Cash balance at period end | $35.9 | $39.3 |
| Cash from business operations* | 9.4 | 11.9 |
| *See table at the back of this earnings release. |
| Q4 2012 | Q4 2011 | |
| Pro forma results | ||
| Net sales | $65.1 | $65.1 |
| Adjusted net income | (11.6) | 4.2 |
| Adjusted EBITDA | 0.9 | 15.1 |
| Adjusted net income per diluted share | ($0.13) | $0.04 |
| Adjusted EBITDA per diluted share | $0.01 | $0.16 |
| Non-GAAP and other measures | ||
| Subscription, maintenance & EDI revenue as % of net sales** | 58.3% | N/A |
| Subscription and non-recurring backlog at period end | $76.9 | $56.2 |
| Days sales outstanding | 102 | 100 |
| **Comparable information for periods prior to 2012 is not available. | ||
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
